Cargando…

Identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma

While cancer immunotherapy has been remarkably successful in some malignancies, some cancers derive limited benefit from current immunotherapies. Here, we combined immune landscape signatures with hepatocellular carcinoma clinical and prognostic features to classify them into distinct subtypes. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Hongmei, Chen, Yuchuan, Wang, Kai, Yu, Lu, Huang, Xixin, Li, Qianyu, Xie, Yuwen, Lin, Jiayu, He, Yueyun, Yi, Xinyu, Wang, Yanzhi, Chen, Longhua, Ding, Yi, Li, Yiyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732284/
https://www.ncbi.nlm.nih.gov/pubmed/33049716
http://dx.doi.org/10.18632/aging.103977
_version_ 1783622059008458752
author Yan, Hongmei
Chen, Yuchuan
Wang, Kai
Yu, Lu
Huang, Xixin
Li, Qianyu
Xie, Yuwen
Lin, Jiayu
He, Yueyun
Yi, Xinyu
Wang, Yanzhi
Chen, Longhua
Ding, Yi
Li, Yiyi
author_facet Yan, Hongmei
Chen, Yuchuan
Wang, Kai
Yu, Lu
Huang, Xixin
Li, Qianyu
Xie, Yuwen
Lin, Jiayu
He, Yueyun
Yi, Xinyu
Wang, Yanzhi
Chen, Longhua
Ding, Yi
Li, Yiyi
author_sort Yan, Hongmei
collection PubMed
description While cancer immunotherapy has been remarkably successful in some malignancies, some cancers derive limited benefit from current immunotherapies. Here, we combined immune landscape signatures with hepatocellular carcinoma clinical and prognostic features to classify them into distinct subtypes. The immunogenomic profiles, stromal cell features and immune cell composition of the subtypes were then systematically analyzed. Two independent prognostic indexes were established based on 6 immune-related genes and 17 differentially expressed genes associated with stromal cell content. These indexes were significantly correlated with tumor mutation burden, deficient DNA mismatch repair and microsatellite instability. In addition, tumor-infiltrating lymphocytes, including activated NK cells, resting memory CD4 T-cells, eosinophils, and activated mast cells were significantly correlated with hepatocellular carcinoma survival. In conclusion, we have comprehensively described the immune landscape signatures and identified prognostic immune-associated biomarkers of hepatocellular carcinoma. Our findings highlight potential novel avenues for improving responses to immunotherapy.
format Online
Article
Text
id pubmed-7732284
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Impact Journals
record_format MEDLINE/PubMed
spelling pubmed-77322842020-12-18 Identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma Yan, Hongmei Chen, Yuchuan Wang, Kai Yu, Lu Huang, Xixin Li, Qianyu Xie, Yuwen Lin, Jiayu He, Yueyun Yi, Xinyu Wang, Yanzhi Chen, Longhua Ding, Yi Li, Yiyi Aging (Albany NY) Research Paper While cancer immunotherapy has been remarkably successful in some malignancies, some cancers derive limited benefit from current immunotherapies. Here, we combined immune landscape signatures with hepatocellular carcinoma clinical and prognostic features to classify them into distinct subtypes. The immunogenomic profiles, stromal cell features and immune cell composition of the subtypes were then systematically analyzed. Two independent prognostic indexes were established based on 6 immune-related genes and 17 differentially expressed genes associated with stromal cell content. These indexes were significantly correlated with tumor mutation burden, deficient DNA mismatch repair and microsatellite instability. In addition, tumor-infiltrating lymphocytes, including activated NK cells, resting memory CD4 T-cells, eosinophils, and activated mast cells were significantly correlated with hepatocellular carcinoma survival. In conclusion, we have comprehensively described the immune landscape signatures and identified prognostic immune-associated biomarkers of hepatocellular carcinoma. Our findings highlight potential novel avenues for improving responses to immunotherapy. Impact Journals 2020-10-13 /pmc/articles/PMC7732284/ /pubmed/33049716 http://dx.doi.org/10.18632/aging.103977 Text en Copyright: © 2020 Yan et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Yan, Hongmei
Chen, Yuchuan
Wang, Kai
Yu, Lu
Huang, Xixin
Li, Qianyu
Xie, Yuwen
Lin, Jiayu
He, Yueyun
Yi, Xinyu
Wang, Yanzhi
Chen, Longhua
Ding, Yi
Li, Yiyi
Identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma
title Identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma
title_full Identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma
title_fullStr Identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma
title_full_unstemmed Identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma
title_short Identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma
title_sort identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732284/
https://www.ncbi.nlm.nih.gov/pubmed/33049716
http://dx.doi.org/10.18632/aging.103977
work_keys_str_mv AT yanhongmei identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma
AT chenyuchuan identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma
AT wangkai identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma
AT yulu identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma
AT huangxixin identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma
AT liqianyu identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma
AT xieyuwen identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma
AT linjiayu identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma
AT heyueyun identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma
AT yixinyu identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma
AT wangyanzhi identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma
AT chenlonghua identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma
AT dingyi identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma
AT liyiyi identificationofimmunelandscapesignaturesassociatedwithclinicalandprognosticfeaturesofhepatocellularcarcinoma